TELO

No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration. MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing therapies that target epigenetic and metabolic drivers of cancer and age-related disease, today announced favorable results from a comprehensive series of IND-enabling Good Laboratory Practice (GLP) toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir). The studies were conducted as part of the Company's ongoing IND-enabling program and evaluated cardiovascular, respiratory, phototoxicity, and repeat-dose toxicology using a combination of in vitro systems and in vivo rat and dog models. While final quality assurance (QA) review of the study reports is ongoing, the Company does not expect the overall conclusions to change. Key Safety Findings Overall Safety: Telomir-1 was well tolerated across all completed GLP safety studies, with no treatment-related adverse or dose-limiting toxicities observed. Cardiovascular Safety: In non-rodent studies, including in dogs, no test-article-related changes in blood pressure, heart rate, electrocardiogram (ECG) parameters, or body temperature were observed following oral administration. In addition, no concerning cardiac safety signals were identified in a validated GLP assay commonly used to assess arrhythmia risk. Repeated-Dose Toxicology: Repeated oral administration in both rats and dogs were well tolerated. Observed findings were limited, reversible, and considered non-adverse, with no serious toxicological findings identified. Respiratory Safety: No clinically meaningful effects on respiratory function were observed. Phototoxicity: Telomir-1 demonstrated no evidence of phototoxic potential under simulated sunlight conditions. Across oral administration studies, Telomir-1 demonstrated consistent systemic exposure and predictable pharmacokinetic behavior, supporting continued advancement toward clinical development. Overall Conclusion Collectively, these IND-enabling GLP data demonstrate a favorable safety and tolerability profile and consistent systemic exposure upon oral administration for Telomir-1. No treatment-related adverse toxicity was observed, an...

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to reverse biological aging and degenerative diseases. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres, and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.” Preclinical test results recently released further confirm the CEO’s statement and our belief in TELO. The company announced that a preclinical study showed that Telomir-1 can reset abnormal DNA methylation patterns, which reverses the cancer-induced gene silencing in tumor suppressors. That’s the scientific way of saying that there are indications that Telomir-1 has the potential to have the ability to fight multiple aggressive cancers—adding to the conditions Telomir-1 has shown indications of being able to treat. Getting into the scientific detail—Telomir-1, according to the company, reverses DNA methylation of CDKN2A, a master tumor suppressor gene silenced in many aggressive cancers. CDKN2A is one of the body's natural defenses against cancer. Also referred to as the "cell cycle brake," this gene tells cells when to stop dividing and helps damaged cells self-destruct. In many cancers, CDKN2A is switched off by abnormal DNA methylation, leaving tumors free to grow unchecked. By resetting this methylation, Telomir-1 appears to turn the brake back on - restoring a critical safeguard that cancer cells had disabled. These results continue the mounting evidence that Telomir-1 has the potential to have a major impact on the worst parts of the aging process, which would have an almost unlimited market potential. We continue to recommend investors take a look at TELO ahead of the human trials that are planned for early next year. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting...

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is among the 10 Best Growth Stocks Under $100 to Buy Now. On Wednesday, Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) revealed that its leading product, Telomir-1, showcased a marked improvement in the neurological, liver, and kidney symptoms observed in a preclinical animal model of Wilson’s disease. In a zebrafish model mimicking Wilson’s disease, the drug showed substantial dose-dependent improvements, including a decrease in tremors, a normal swimming behavior, and a 50% reduction in copper accumulation in liver tissue. It also led to better liver and kidney histopathology while restoring key biomarkers. As Dr. Angel, Chief Scientific Advisor at Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), mentioned, A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment. With a market capitalization of $59.079 million, the company is also positioning its drug through IND-enabling studies, with plans to submit its first IND for a rare disease by the year’s end, followed by human trials in the first half of the next year. Analysts have set a price target of $15.50 for Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), implying an upside of a whopping 688%. These well-structured plans highlight the company’s position to lead the global market in the years ahead. Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a pre-clinical stage biopharmaceutical company that emphasizes the reversal of oxidative stress, cellular protection, and regulatory mechanisms. Incorporated in 2021, this Florida-based company is designing and developing products to address the causes of rare diseases. While we acknowledge the potential of TELO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.” The company continues to expand its potential portfolio and just announced some of the most encouraging test results to date for the approximately 20 million Americans suffering from age-related macular degeneration (AMD) (CDC). Preclinical results from a study evaluating Telomir-1 in a genetically modified zebrafish model of AMD. According to the company, following a 14-day oral dosing regimen, Telomir-1 reversed central vision response and vision acuity, restored retinal degeneration and architecture, and significantly reduced oxidative stress. The company detailed the results by noting that the zebrafish showed clear signs of neurodegeneration and visual impairment. Analysis showed that the animals had approximately 15% total retinal degeneration, which affected multiple critical layers. The inner nuclear layer (INL) was thinned. This layer acts as the retina’s central processing zone, where signals from light-sensitive photoreceptors are refined before being passed deeper into the eye. The ganglion cell layer (GCL) was degraded. This layer contains neurons that form the optic nerve, which sends visual information to the brain. Damage here disrupts vision at its source. The inner plexiform layer (IPL) volume was reduced. IPL is a retinal layer located between the inner nuclear layer (INL) and the ganglion cell layer (GCL). It may contribute to disease processes through inner retinal changes, inflammation, or vitreoretinal interactions. The outer plexiform layer (OPL) showed early deterioration. This layer connects photoreceptors to other retinal cells and is essential for detecting changes in light and contrast. After receiving Telomir-1, the company reported that the treated animals showed a substantial recovery, which included structural retina...

By Brad Sorensen, CFA NASDAQ:TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere caps. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.” The company continues to learn about the potential uses for Telomir-1 and just announced preclinical data that showed the treatment showed signs of reversing multiple signs of cellular decline across human cell lines. Cellular decline and stress is associated with symptoms associated with aging and multiple chronic diseases. The study showed that Telomir-1 improved mitochondrial activity, reduced oxidative stress, restored calcium balance, and protects from toxic metal effects. Reversing the negative impacts of these areas can help improve immune defense, slow degenerative conditions, and potential prevent energy loss that drives aging and multiple chronic diseases. For example, company management believes that these results provide a foundation for the company’s research initiatives in autism spectrum disorder and spasmodic dysphonia. This announcement adds to the list of conditions that Telomir-1 has the potential to treat by attacking the underlying causes of the conditions and not just the symptoms. The company is continuing to zero in on all of the mechanisms that cause Telomir-1 to have these positive impacts and recently explained that Telomir-1 is designed to normalize iron homeostasis, reducing oxidative stress and improving insulin sensitivity, setting it apart from existing drugs that primarily treat symptoms without addressing these underlying causes. Excess iron levels contribute to oxidative stress, beta-cell damage, and insulin resistance across key tissues and reducing these levels could have a major impact on a wide variety of conditions. It's this extensive experience and record of success, combined with the test results we’ve seen at this stage of the process that makes us get excited about the potential for Telomir-1 and the comp...